Tivic Health Announces 2025 Annual Meeting of Stockholders, to be held virtually on June 30, 2025.

Tivic Health Systems will hold its Virtual Annual General Meeting of Shareholders on June 30, 2025, at 1:00 PM PT / 4:00 PM ET. The meeting will be conducted virtually and accessible online, and stockholders can submit questions for management's consideration through the virtual platform. Only stockholders of record at the close of business on May 14, 2025, are entitled to notice and vote at the meeting.

Tivic Health Systems, Inc. (Nasdaq: TIVC), a diversified therapeutics company, has announced that its Virtual Annual General Meeting of Shareholders will be held on Monday, June 30, 2025, at 1:00 PM Pacific Time (PT) or 4:00 PM Eastern Time (ET). The meeting, which will be conducted virtually, aims to provide a consistent and convenient experience for all stockholders regardless of their location.

Stockholders of record of shares of Tivic Health’s common stock at the close of business on May 14, 2025, are entitled to notice and to vote at the meeting. To attend the virtual meeting and participate, stockholders will need to use the control number included on the proxy card they received in the mail or log into their brokerage firm’s website to access the meeting through their stockholder communication mailbox. Detailed instructions for accessing the meeting are provided on the voting instruction card sent by the broker, bank, or other nominee.

The company’s Proxy Statement, proxy card, and Annual Report on Form 10-K for the year ended December 31, 2024, are available on the Internet at: SEC Filings - Tivic Health.

Tivic Health Systems is focused on harnessing the power of the immune and autonomic nervous systems to fight disease and restore health. The company’s bioelectronic program aims to develop personalized, non-invasive therapeutic devices for vagus nerve stimulation to improve clinical outcomes in inflammatory, neurologic, and cardiac diseases. Additionally, Tivic Health has developed ClearUP®, a product that provides temporary relief of sinus pain, pressure, and congestion, and is available through top-tier online retail and distribution partners. The company’s newly formed biopharmaceutical program is focused on commercial advancements of the toll-like receptor 5 drugs Entolimod™ and Entolasta™, including lead product candidate Entolimod for acute radiation syndrome.

The press release also includes forward-looking statements, which are subject to substantial risks and uncertainties. These statements are based on the company’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Investors are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading “Risk Factors,” as well as the company’s subsequent filings with the SEC.

For more information about Tivic Health, visit https://ir.tivichealth.com.

References:

[1] https://www.businesswire.com/news/home/20250624978604/en/Tivic-Health-Announces-2025-Annual-Meeting-of-Stockholders
[2] https://www.stocktitan.net/news/TIVC/tivic-health-announces-2025-annual-meeting-of-qfk0fdydr530.html